258 Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial. (12th April 2019) - Tahir, Hasan; Mease, Philip J; Kavanaugh, Arthur; Reimold, Andreas; Rech, Jürgen; Hall, Stephen; Geusens, Piet; Pellet, Pascale; Delicha, Eumorphia Maria; Pricop, Luminita; Mpofu, Shephard